Rekombinanter TcdB Antikörper

Produktnummer ABIN7566457

Dieser Human Monoklonal Antikörper detektiert spezifisch TcdB in ELISA, Func und WB. Es zeigt Reaktivität gegenüber Proben von Clostridium difficile.

Kurzübersicht für Rekombinanter TcdB Antikörper (ABIN7566457)

Target: TcdB

Antikörpertyp: Recombinant Antibody

Reaktivität: Clostridium difficile

Wirt: Human

Klonalität: Monoklonal

Applikation: ELISA, Functional Studies (Func), Western Blotting (WB)

Klon: VIF090-A6

Produktdetails

Verwendungszweck: anti-TcdB (Clostridioides difficile extoxin), mAb (rec.) (VIF090-A6)

Produktmerkmale:

Recombinant Antibody. Recognizes TcdB from Clostridioides difficile. Applications: ELISA, FUNC, WB. Clone: VIF090-A6. Isotype: Human IgG1. Formulation: Liquid. In PBS. Clostridioides difficile is a spore-forming, anaerobic, and gram-positive bacterium, that opportunistically colonizes human colon and induces diseases such as diarrhea and pseudomembranous colitis. The symptoms of C. difficile infection (CDI) are mainly caused by two primary exotoxins, TcdA and TcdB, released from the bacterium. Both TcdA and TcdB belong to the family of large clostridial toxins (LCTs), which contain an N-terminal glucosyltransferase domain that modifies small GTPase proteins, a cysteine protease domain (CPD) that autocatalytically cleave the holotoxin in the cytosol, a combined domain for both delivery and receptor binding, and a C-terminal region consisting of series of combined repetitive oligopeptides (CROPs). These toxins enter host cells via receptor-mediated endocytosis and inactivate small GTPase proteins, leading to actin cytoskeleton disruption and cell death. Of the two toxins, TcdB alone is able to induce a full spectrum of diseases in both animals and humans. Although different toxin receptors have been identified, it is no valid therapeutic option to prevent receptor endocytosis. Neutralizing antibodies, directly targeting both toxins are so far the only therapeutic approaches.

Clostridioides difficile is a spore-forming, anaerobic, and gram-positive bacterium, that opportunistically colonizes human colon and induces diseases such as diarrhea and pseudomembranous colitis. The symptoms of C. difficile infection (CDI) are mainly caused by two primary exotoxins, TcdA and TcdB, released from the bacterium. Both TcdA and TcdB belong to the family of large clostridial toxins (LCTs), which contain an N-terminal glucosyltransferase domain that modifies small GTPase proteins, a cysteine protease domain (CPD) that autocatalytically cleave the holotoxin in the cytosol, a combined domain for both delivery and receptor binding, and a C-terminal region consisting of series of combined repetitive oligopeptides (CROPs). These toxins enter host cells via receptor-mediated endocytosis and inactivate small GTPase proteins, leading to actin cytoskeleton disruption and cell death. Of the two toxins, TcdB alone is able to induce a full spectrum of diseases in both animals and humans. Although different toxin receptors have been identified, it is no valid therapeutic option to prevent receptor endocytosis. Neutralizing antibodies, directly targeting both toxins are so far the only therapeutic approaches.

Aufreinigung: Puified

Reinheit: >95 % (SDS-PAGE)

Immunogen: Recombinant TcdB (Clostridioides difficile, strain VPI10463) containing a C-terminal His-tag.

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: In PBS.

Handhabung: After opening, prepare aliquots and store at -20 °C.Avoid freeze/thaw cycles.Please handle under sterile conditions to avoid contamination.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung:

Stable for at least 1 year after receipt when stored at -20°C.

Stable for at least 1 week when stored at +4°C.

Antigendetails

Target: TcdB

UniProt: Q189K3